Nifedipine gastrointestinal therapeutic system versus nifedipine coat- core: Comparison of efficacy via 24-hour ambulatory blood pressure monitoring

Annals of Pharmacotherapy

Volumn 31, Issue 7-8, 1997, Pages 819-822

  Defina, Laura F ^a   Bookstaver, David A ^b,c   Goldfinger, Michael P ^c   Coffey, Timothy A ^d  

^a Dallas Diagnostic Association   (United States)

^b Department of Pharmacy   (United States)

^c Dwight David Eisenhower Army Med C   (United States)

^d General Internal Medicine Service   (United States)

Author keywords

Formulation; Hypertension; Nifedipine

Indexed keywords

NIFEDIPINE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DYSPNEA; EPISTAXIS; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0030762987     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100701     Document Type: Article

References (14)

1. Olivari MT, Bartorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi MD. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 1979;59:1056-62.
2. Martin AM, Simon Q, Extremera BG, Garcia MA, Martinez MR, Luengo MA. Metabolic and antihypertensive effects of nifedipine in hypertensive patients. J Cardiovasc Pharmacol 1992;19(suppl 2):S57-9.
3. Saano V, Raatikainen O, Paronen P, Komulainen H. Pharmacokinetics and acute side-effects of nifedipine given as slow-release tablets or liquid-filled capsules. Int J Clin Pharmacol Res 1989;9:247-54.
4. Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid JL. Nifedipine: individual responses and concentration-effect relationships. Hypertension 1988;12:443-9.
5. Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: a controlled-release formulation of nifedipine. Am J Med 1987;83(suppl 6B):10-4.
6. Package insert. Procardia XL (nifedipine). New York: Pratt Pharmaceutical Division of Pfizer Inc., 1994.
7. Package insert. Adalat CC (nifedipine). West Haven, CT: Bayer Corporation, 1995.
8. Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained-release formulation of nifedipine. J Clin Pharmacol 1990;30:1012-9.
9. Krakoff LR. Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH trial. J Cardiovasc Pharmacol 1993;21(suppl 2):S14-7.
10. Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. Drugs 1994;48(suppl 1):23-31.
11. Missouris CG, Cappuccio FP, Markandu ND, Singer DR, MacGregor GA. Double-blind crossover study of once daily nifedipine coat core in essential hypertension. J Hum Hypertens 1994;8:289-92.
12. Granberry MC, Gardner SF, Schneider EF, Carter IR. Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring. Pharmacotherapy 1996;16:932-6.
13. The National High Blood Pressure Education Program Coordinating Committee. National High Blood Pressure Education Program Working Group report on ambulatory blood pressure monitoring. Arch Intern Med 1990;150:2270-80.
14. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.